Price to Sales (P/S)
since 2005
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Amgen Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Amgen Inc. Annual Report.
The price-to-sales (P/S) ratio for the period examined exhibits considerable fluctuation, though generally trends downward over the long term. Initial values are relatively high, followed by a period of decline, a subsequent rise, and then a renewed decline towards the end of the observed timeframe. The ratio demonstrates sensitivity to changes in both share price and sales per share.
- Initial Decline (2006-2008)
- From 2006 to 2008, the P/S ratio decreased significantly from 7.24 to 3.46. This decline coincided with a decrease in share price and a moderate increase in sales per share. The larger decrease in share price contributed more significantly to the overall reduction in the P/S ratio.
- Period of Stabilization and Increase (2009-2014)
- Between 2009 and 2014, the P/S ratio experienced a period of relative stability, followed by an increase. The ratio fluctuated between approximately 3.44 and 6.13. This period saw increases in both share price and sales per share, with the share price increase being the primary driver of the ratio’s upward movement.
- Recent Fluctuations and Decline (2015-2026)
- From 2015 onwards, the P/S ratio demonstrated more pronounced fluctuations. It peaked at 6.13 in 2015, then decreased to 5.10 in 2021. A subsequent increase to 5.78 in 2023 was followed by a decline to 4.88 in 2025 and a rise to 5.66 in 2026. Sales per share increased consistently during this period, but the P/S ratio’s movement was more heavily influenced by share price volatility.
- Overall Trend
- Despite the intermediate fluctuations, a general downward trend in the P/S ratio is observable over the entire period. The ratio began at 7.24 in 2006 and concluded at 5.66 in 2026. This suggests that, relative to sales, the market valuation of the company has decreased over time. However, the ratio remains within a reasonable range, and the fluctuations indicate responsiveness to market conditions and company performance.
The observed changes in the P/S ratio suggest a dynamic relationship between investor sentiment, company performance as reflected in sales, and market valuation. Further investigation into the underlying factors driving share price and sales per share would be necessary to fully understand these trends.
Comparison to Competitors
Amgen Inc., P/S, long-term trends, comparison to competitors
| Amgen Inc. | AbbVie Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | ||||||||||||
| Feb 14, 2025 | ||||||||||||
| Feb 14, 2024 | ||||||||||||
| Feb 9, 2023 | ||||||||||||
| Feb 16, 2022 | ||||||||||||
| Feb 9, 2021 | ||||||||||||
| Feb 12, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 13, 2018 | ||||||||||||
| Feb 14, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 19, 2015 | ||||||||||||
| Feb 24, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 29, 2012 | ||||||||||||
| Feb 25, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 28, 2008 | ||||||||||||
| Feb 28, 2007 | ||||||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Amgen Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Amgen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Amgen Inc., P/S, long-term trends, comparison to industry (health care)
| Amgen Inc. | Health Care | |
|---|---|---|
| Feb 13, 2026 | ||
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).